Table 1 Key characteristics of published pharmacokinetics studies of imipenem in critically ill patients undergoing CRRT [2, 9,10,11,12,13,14,15,16,17,18]
References | CRRT mode | SC or SA | Vd (L/kg) | CLNR (ml/min) | CLCRRT (ml/min) | Pre-specified PD target | Dose recommendation |
|---|---|---|---|---|---|---|---|
Keller et al. [20] | CAVH | 1.16 | 0.29 | 108.5 ± 29.6 | 7.0 ± 3.4 | NS | NS |
Przechera et al. [16] | CAVH | 1.13 ± 0.12 | 0.47 ± 0.16 | – | 6.49 | NS | NS |
Vos et al. [18] | CAVH CAVHD | SC: 1.05 ± 0.19 | – | – | 9 ± 3 (CVVH) 16 ± 7 (Qd 1 L/h) 30 ± 7 (Qd 3 L/h) | NS | NS |
Mueller et al. [2] | CVVH | 0.8 | 0.33 ± 0.09 | 95 ± 13.8 | 13.3 | NS | NS |
Hashimoto et al. [24] | CVVHD | – | 0.38 ± 0.13 | 70.62 ± 14.6 | 18.74 ± 1.2 | NS | NS |
Fish et al. [23] | CVVH CVVHDF | 1.21 ± 0.11 (CVVH), 1.28 ± 0.17 (CVVHDF) | 0.36 ± 0.1 (CVVH), 0.37 ± 0.13 (CVVHDF) | 109 ± 24 (CVVH), 120 ± 32 (CVVHDF) | 36 ± 13 (CVVH), 57 ± 28 (CVVHDF) | Yes | Yes |
Afshartous et al. [21] | CVVHD | – | 0.32 | – | 32.4 ± 9.8* | Yes | NS |
Boucher et al. [22] | CVVH | 1.01 ± 0.12 | 0.39 ± 0.27 | 191.5 | 54.5 | No | NS |
Wen et al. [19] | CVVHDF CVVH | – | 0.37 ± 0.19 (CVVHDF) 1.11 (CVVH) | – | 1.9 mL/min/kg (CVVHDF) 2.8 mL/min/kg (CVVH) | Yes | NS |
Breilh et al. [26] | CVVH | 0.52–0.80 | 0.33 | 236.59 | 32.62 | Yes | NS |